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Freeman-Sheldon syndrome, or distal arthrogryposis type 2A (DA2A), is an autosomal-dominant condition caused by mutations in
MYH3 and characterized by multiple congenital contractures of the face and limbs and normal cognitive development. We identified
a subset of five individuals who had been putatively diagnosed with ‘‘DA2A with severe neurological abnormalities’’ and for whom
congenital contractures of the limbs and face, hypotonia, and global developmental delay had resulted in early death in three cases;
this is a unique condition that we now refer to as CLIFAHDD syndrome. Exome sequencing identifiedmissensemutations in the sodium
leak channel, non-selective (NALCN) in four families affected by CLIFAHDD syndrome. We used molecular-inversion probes to screen
for NALCN in a cohort of 202 distal arthrogryposis (DA)-affected individuals as well as concurrent exome sequencing of six other
DA-affected individuals, thus revealing NALCN mutations in ten additional families with ‘‘atypical’’ forms of DA. All 14 mutations
were missense variants predicted to alter amino acid residues in or near the S5 and S6 pore-forming segments of NALCN, highlighting
the functional importance of these segments. In vitro functional studies demonstrated that NALCN alterations nearly abolished the
expression of wild-type NALCN, suggesting that alterations that cause CLIFAHDD syndrome have a dominant-negative effect. In
contrast, homozygosity for mutations in other regions of NALCN has been reported in three families affected by an autosomal-recessive
condition characterized mainly by hypotonia and severe intellectual disability. Accordingly, mutations in NALCN can cause either a
recessive or dominant condition characterized by varied though overlapping phenotypic features, perhaps based on the type of muta-
tion and affected protein domain(s).Distal arthrogryposis (DA) is a group of at least ten disor-
ders that are characterized by non-progressive congenital
contractures of two or more body areas and that typically
affect the wrists, hands, ankles, and feet.1 The three
most common DA syndromes are DA1 (MIM 108120),1,2
DA2A (Freeman-Sheldon syndrome [MIM 193700]),3
and DA2B1,2 (Sheldon-Hall syndrome [MIM 601680]).
DA1 and DA2B can be caused by variants in any one of
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suggestive of a distinctive and previously unrecognized
multiple-malformation syndrome. Specifically, we identi-
fied a subset of five families, each with an affected child
born to unaffected parents, in which the proband had
congenital contractures of the limbs (hands and/or feet)
and face; abnormal tone, most commonly manifested as
hypotonia; neonatal respiratory distress; and develop-
mental delay. These features are collectively referred to as
CLIFAHDD syndrome (Table 1, families A–E; Figure 1; Fig-
ures S1 and S2).
Facial characteristics shared among individuals with
CLIFAHDD syndrome include downslanting palpebral
fissures, a broad nasal bridge with an anteverted nasal tip
and large nares, a short columella, a long philtrum, deep
nasolabial folds, micrognathia, pursed lips, and chin
dimpling resembling the ‘‘H-shaped’’ dimpling observed
in persons with DA2A (Figure 1). Each person in our subset
had camptodactyly with adducted thumbs, as well as posi-
tional foot deformities ranging from mild varus deformity
to severe clubfoot. Additionally, contractures of the el-
bows, knees, and hips, as well as a short neck and scoliosis,
were observed.
Neurological evaluation of each living child with
CLIFAHDD syndrome revealed a global developmental
delay manifesting as speech, motor, and cognitive delays
that varied from mild to severe, as well as hypotonia and
seizures. Magnetic resonance imaging of the brain, con-
ducted on four of the affected persons, was reported as
normal in two persons and abnormal in two. Of the latter,
one person was reported to have cerebral and cerebellar at-
rophy and another to have cerebral atrophy and a ‘‘small
pituitary.’’ Severe gastresophageal reflux was observed in
all three individuals for whom data were available, and
four of five individuals had inguinal hernias. Three of the
five affected individuals died in infancy or early childhood.
One of these three individuals died of hemophagocytosis
complications in the newborn period, whereas the exact
cause of death was unclear in the other two.
To find the mutation-harboring gene(s) in individuals
with CLIFAHDD syndrome, we first screened the puta-
tively CLIFAHDD-syndrome-diagnosed probands from
each of the five families by performing Sanger sequencing
for mutations in genes, other than MYH3, known to cause
DA1, DA2A, and DA2B. Each proband with CLIFAHDD
syndrome was also screened for copy-number variations
(CNVs) by comparative genome-wide array genomic hy-
bridization on the Illumina HumanCytoSNP-12. No path-
ogenic mutations or shared CNVs were identified. Next,
exome sequencing was performed on four CLIFAHDD-
syndrome-affected parent-child trios for whom sufficient
quantities of DNA were available. All studies were
approved by the institutional review boards of the Univer-
sity of Washington and Seattle Children’s Hospital, and
informed consent was obtained from participants or their
parents.
1 mg genomic DNA was subjected to a series of shotgun-
library construction steps, including fragmentationThe Amethrough acoustic sonication (Covaris), end polishing
(NEBNext End Repair Module), A-tailing (NEBNext dA-
Tailing Module), and PCR amplification with ligation of
8 bp barcoded sequencing adaptors (Enzymatics Ultrapure
T4 Ligase) for multiplexing. We hybridized 1 mg of bar-
coded shotgun library to capture probes targeting ~36.5
Mb of coding exons (Roche Nimblegen SeqCap EZ Human
Exome Library v.2.0). Library quality was determined by
examination of molecular-weight distribution and sample
concentration (Agilent Bioanalyzer). Pooled, barcoded
libraries were sequenced via paired-end 50 bp reads with
an 8 bp barcode read on Illumina HiSeq sequencers.
Demultiplexed BAM files were aligned to a human refer-
ence (UCSC Genome Browser hg19) via the Burrows-
Wheeler Aligner (BWA) v.0.6.2. Read data from a flow-cell
lane were treated independently for alignment and qual-
ity-control purposes in instances where the merging of
data from multiple lanes was required. All aligned read
data were subjected to (1) removal of duplicate reads (Pic-
ard MarkDuplicates v.1.70), (2) indel realignment (GATK
IndelRealigner v.1.6-11-g3b2fab9), and (3) base-quality re-
calibration (GATK TableRecalibration v.1.6-11-g3b2fab9).
Variant detection and genotyping were performed with
GATK UnifiedGenotyper (v.1.6-11-g3b2fab9). Variant
data for each sample were formatted (variant-call format)
as ‘‘raw’’ calls that contained individual genotype data for
one or multiple samples and were flagged with the filtra-
tion walker (GATK) so that lower-quality sites and poten-
tial false positives (e.g., strand bias > 0.1, quality scores
(QUAL) % 50, allelic imbalance (ABHet) R 0.75, long ho-
mopolymer runs (HRun) > 3, and/or low quality by depth
(QD) < 5).
Variants with an alternative allele frequency >0.005 in
the NHLBI Exome Sequencing Project Exome Variant
Server (ESP6500) or the 1000 Genomes Browser or >0.05
in an internal exome database of ~700 individuals were
excluded prior to analysis. Additionally, variants that
were flagged as low quality or potential false positives
(quality score % 30, long homopolymer run > 5, low
quality by depth < 5, within a cluster of SNPs) were also
excluded from analysis. Variants that were only flagged
by the strand-bias filter (strand bias > 0.10) were
included in further analyses because the strand-bias
flag has previously been found to be applied to valid vari-
ants. CNV calls were also generated from exome data
(CoNIFER).6 Variants were annotated with the Seattle-
Seq137 Annotation Server, and variants for which the
only functional prediction label was ‘‘intergenic,’’ ‘‘cod-
ing-synonymous,’’ ‘‘UTR,’’ ‘‘near-gene,’’ or ‘‘intron’’ were
excluded. Individual genotypes with depth < 6 or geno-
type quality < 20 were treated as missing.
By analysis of variants from exome sequencing under a
de novo mutation model, we identified four different de
novo variants in a single gene, NALCN, encoding a sodium
leak channel (NALCN [MIM 611549; Refseq accession
number NM_052867.2]), in four CLIFAHDD-syndrome-
affected families (Table 1 and Figure 1, Families A–D;rican Journal of Human Genetics 96, 462–473, March 5, 2015 463
Table 1. Mutations and Clinical Findings For Individuals with CLIFAHDD Syndrome
Family A Family B Family C Family D Family E Family F Family G
Original Diagnosis CLIFAHDD CLIFAHDD CLIFAHDD CLIFAHDD CLIFAHDD DA2A DA2A
Mutation Information
Exon (NALCN) 6 9 15 39 31 8 13
cDNA change c.530A>C c.938T>G c.1768C>T c.4338T>G c.3493A>C c.934C>A c.1526T>C
Predicted protein alteration p.Gln177Pro p.Val313Gly p.Leu590Phe p.Ile1446Met p.Thr1165Pro p.Leu312Ile p.Leu509Ser
GERP 4.92 6.16 5.94 4.73 5.2 6.16 5.11
CADD 1.0 (phred-like) 19.22 25.9 23.9 16.08 21.0 32.0 22.6
Polyphen-2 (HumVar) 1.0 1.0 0.996 0.995 0.969 1.0 1.0
Clinical Features: Face
Downslanting palpebral fissures – þ ND þ þ þ þ
Strabismus – þ ND þ þ þ þ
Esotropia – þ ND – þ – –
Broad nasal bridge þ þ þ þ þ þ þ
Anteverted nasal tip þ þ þ þ þ – þ
Large nares þ þ þ þ þ þ þ
Short columella þ þ þ þ þ þ þ
Long philtrum þ þ þ þ þ þ þ
Micrognathia þ þ þ þ þ þ þ
Pursed lips þ þ þ þ þ – þ
H-shaped dimpled chin þ þ þ þ – þ þ
Deep nasolabial folds þ þ þ þ þ – þ
Full cheeks þ þ þ þ þ þ –
Clinical Features: Limbs
Camptodactyly þ þ þ þ þ þ þ
Ulnar deviation þ þ þ þ þ þ þ
Adducted thumbs þ þ þ þ þ þ þ
Clubfoot þ þ þ L metatarsus adductus þ þ
Calcaneovalgus deformity – þ – R – – –
Hip contractures þ þ þ BL dislocation – – þ
Elbow contractures þ þ þ – – þ
Knee contractures þ – þ þ – þ þ
Other Clinical Features
Scoliosis þ þ – þ – ND þ
Short neck þ þ þ þ þ ND þ
Cognitive delay NDa þ NDa þ þ þ –
This table provides a summary of clinical features of affected individuals from families in which mutations in NALCN were identified. Clinical characteristics
listed in the table are primarily features that distinguish CLIFAHDD syndrome from DA conditions. Abbreviations are as follows: þ, presence of a finding; ,
absence of a finding; ND, no data were available; NA, not applicable; GERP, genomic evolutionary rate profiling; CADD, combined annotation-dependent
depletion; CLIFAHDD, congenital contractures of the limbs, face, hypotonia, and developmental delay; DA2A, distal arthrogryposis type 2A; DA2B, distal
arthrogryposis type 2B; DA1, distal arthrogryposis type 1; VSD, ventricular septal defect; and GERD, gastresophageal reflux disease. cDNA positions are
provided as named by the HGVS MutNomen web tool relative to NM_052867.2.
aChild died before an assessment could be made.
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Family H Family I Family J Family K Family L Family M Family N
DA2A DA2B DA2B DA2B DA2B DA1 DA1
26 9 13 14 31 13 26
c.3017T>C c.979G>A c.1538C>A c.1733A>C c.3542G>A c.1534T>G c.3050T>C
p.Val1006Ala p.Glu327Lys p.Thr513Asn p.Tyr578Ser p.Arg1181Gln p.Phe512Val p.Ile1017Thr
5.03 6.16 5.11 5.3 5.2 5.11 5.03
24.2 36.0 25.5 23.7 20.5 24.6 17.54
0.999 1.0 1.0 1.0 0.444 1.0 1.0
þ ? þ þ þ – þ
þ – þ – – – –
– – – þ – – –
þ þ þ þ þ þ þ
þ þ þ – þ þ þ
þ þ þ þ þ þ þ
þ þ þ þ þ þ þ
þ þ þ þ – – þ
þ þ þ þ þ þ –
– – þ þ þ – ?
– – þ – þ – –
þ þ – þ þ þ þ
þ þ þ þ þ þ þ
þ þ þ þ þ þ þ
þ þ þ þ þ þ þ
þ þ þ þ þ þ þ
mild L varus þ þ þ – mild varus þ
– – – – – þ –
– þ þ þ þ internally rotated þ
þ þ – þ – –
þ þ – þ þ – –
– – – þ – lumbar lordosis –
– þ – þ þ þ
þ þ þ þ þ þ þ
(Continued on next page)
The American Journal of Human Genetics 96, 462–473, March 5, 2015 465
Table 1. Continued
Family A Family B Family C Family D Family E Family F Family G
Speech delay NA þ NA þ þ þ þ
Motor delay þ þ þ þ þ þ þ
Seizures þ þ – – – – –
Questionable seizure
activity or abnormal
breathing, loss of
motor control
ND þ ND abnormal
discharges
periods of
rigidity
þ þ
MRI findings normal mild cerebral and
cerebellar atrophy
ND generalized cerebral
atrophy, small pituitary
normal cerebellar atrophy normal
Hypotonia no yes yes yes yes yes no
Respiratory insufficiency þ þ þ þ þ apneic episodes in
newborn period
–
Abnormal respiratory
pattern in newborn period
þ þ þ þ þ þ –
Excessive drooling ND ND ND þ
GERD ND þ ND þ þ þ ND
Constipation ND occasional ND – þ
Hernia – inguinal inguinal inguinal / peri umbilical inguinal – inguinal
Age at time of death 6 months 5 years 4 months NA NA NA NA
Other central apnea, uric
acid renal stones
11 pairs of ribs,
abnormal pelvis
and scapulae
renal calcifications suspected fatty acid
oxidation defectFigures S1 and S2). Concurrent exome sequencing of six
DA-affected trios in whom no pathogenic variants in genes
previously associated with DA had been identified seren-
dipitously revealed de novo NALCN variants in two fam-
ilies (Table 1, families G and K; Figure S3). All six variants
were missense variants predicted to be deleterious and to
result in amino acid substitutions of highly conserved
amino acid residues (i.e., the minimum genomic evolu-
tionary rate profile score was 4.73) in NALCN (Table 1
and Figure 2). Each variant was confirmed by Sanger
sequencing to have arisen de novo, and none of the six var-
iants were found in over 71,000 control exomes recorded
in the ESP6500, 1000 Genomes phase 1 (November,
2010 release), internal databases (> 1,400 chromosomes),
or the Exome Aggregation Consortium (ExAC) browser
(October 20, 2014 release).
Because the phenotype of the individuals with muta-
tions in NALCN was variable and overlapped with other
DA syndromes, we used molecular inversion probes with
5-bp molecular tags7 (smMIPs; designed with MIPGen8
v.0.9.7) to conduct targeted next-generation sequencing
of NALCN in 202 additional samples from DA-affected
individuals in whom no pathogenic mutation had been
found. The 43 coding exons (5,214 bp total) of Ensembl
transcript ENST00000251127 and the 10 bp flanking
each exon (860 bp total) were targeted with smMIPs for
an overall target size of 6,074 bp. Pooled and phosphory-
lated smMIPs were added to the capture reactions with
100 ng of genomic DNA from each individual to produce466 The American Journal of Human Genetics 96, 462–473, March 5a NALCN library for each individual. The libraries were
amplified during 21 cycles of PCR, during which an 8-bp
sample barcode was introduced. The barcoded libraries
were then pooled and purified with magnetic beads. After
Picogreen quantification to determine the appropriate
dilution, 10 pmol of the pool was sequenced on an
Illumina MiSeq. Molecular-inversion-probe collapsing
and arm trimming (MIPGenM v.1.0), alignment (BWA
v.0.7.8), and multi-sample genotype calling (GATK Unified
Genotyper v.3.2-2-gec30cee) were performed, and variants
were annotated with SeattleSeq138. We used the same
filtering strategy employed in our analysis of the exome
sequences to select variants for further confirmation by
Sanger sequencing.
Missense variants predicted to result in substitution
of conserved amino acid residues were identified and
confirmed to have arisen de novo in eight additional fam-
ilies: one CLIFAHDD-syndrome-affected family that had
not been available for exome sequencing (Table 1), two
families in which affected members were originally diag-
nosed with DA2A (Table 1, families F and H; Figure S1;
Figure S3, family F), three families in which affected mem-
bers were originally diagnosed with DA2B (Table 1, families
I, J, and L; Figure S1; Figure S2, families I and J), and two
families in which affected members were diagnosed
with DA1 (Table 1, families M and N; Figure S1;
Figure S3, family M). Altogether, we discovered unique,
de novo missense NALCN mutations in fourteen simplex
families in which the proband had been diagnosed with, 2015
Family H Family I Family J Family K Family L Family M Family N
þ þ þ þ þ þ þ
þ þ þ þ þ þ þ
– – – – – – –
ND ND þ þ seizure-like activity with fever ND irregular breathing
ND ND diffuse cerebellar atrophy ND normal normal white matter edema
yes ND no no no? yes no
ND ND ND þ ND – þ
ND ND ND þ þ – þ
ND ND þ þ þ ND ND
– þ þ þ þ in infancy –
ND ND þ þ þ ND ND
– inguinal inguinal inguinal ND umbilical –
NA NA NA NA NA NA NA
cleft palate mitral valve prolapse small VSDCLIFAHDD syndrome (n¼ 5), DA2A (n¼ 3), DA2B (n¼ 4),
or DA1 (n ¼ 2) (Table 1 and Figure 2).
The diagnosis of CLIFAHDD syndrome was considered
in one additional DA2A case brought to our attention
because of a pattern of congenital facial and limb con-
tractures characteristic of DA2A in the absence of a finding
of a pathogenicMYH3mutation. However, death occurred
within two hours of birth at 29 weeks gestation, and the
available clinical information was therefore considered
too limited. This approach proved prudent given that
no mutation in NALCN was identified by exome
sequencing. Instead, this child was found to be a com-
pound heterozygote in RYR1 (MIM 180901) for a pre-
dicted nonsense variant, p. Tyr3921Ter (c.11763C>A
[RefSeq NM_000540.2]), inherited from the father, and a
missense variant, p.Gly341Arg (c.1021G>A [RefSeq
NM_000540.2]), inherited from the mother. The missense
variant has been previously reported to cause malignant
hyperthermia, and persons carrying this variant had a pos-
itive ‘‘in vitro contractility test.’’9 Crisponi syndrome10,11
(MIM 601378) was also considered as a possible diagnosis
for this child. However, no candidate variants were
identified in CRLF1 (MIM 604237), either in this child or
in any of the fourteen families in which NALCN muta-
tions were identified. In addition, we have previously
found two mutations in RYR1 (i.e., c.1391A>G
[p.Gln464Arg] and c.2683-1G>A) in a child diagnosed
with DA2A, suggesting that mutations in RYR1 are a rare
cause of DA2A.The AmeMutations in NALCN have recently been reported to
cause an autosomal-recessive condition, infantile hypoto-
nia with psychomotor retardation and characteristic
facies (IHPRF [MIM 615419]), in one Turkish family12
and two Saudi Arabian13 families. Individuals affected
by CLIFAHDD syndrome share some of the phenotypic
characteristics of IHPRF (e.g., developmental delay and
hypotonia). However, these are relatively non-specific
findings, and IHPRF and CLIFAHDD syndrome appear to
be otherwise distinct from one another. In addition, the
parents of children with IHPRF are carriers of NALCN
mutations but reportedly do not have any of the abnor-
malities found in persons with CLIFAHDD syndrome.
Furthermore, each inherited NALCN variant found in the
14 individuals with CLIFAHDD syndrome was also present
in ESP6500 and/or 1000 Genomes data. This finding sug-
gests that these inherited variants are polymorphisms
rather than pathogenic variants underlying CLIFAHDD
syndrome. Together, these results support the hypothesis
that CLIFAHDD syndrome is an autosomal-dominant con-
dition distinct from IHPRF.
We next sought to explore the mechanism by which
variants in NALCN result in CLIFAHDD syndrome. To
this end, we constructed two expression plasmids
carrying NALCN variants: pcDNA3-hNALCN-L509S-GFP
with c.1526>T(p.Leu509Ser) found in a person with
relatively mild developmental delay (Table 1, family
G) and pcDNA3-hNALCN-Y578S-GFP with c.1733A>C
(p.Tyr578Ser) found in a child with severe developmentalrican Journal of Human Genetics 96, 462–473, March 5, 2015 467
Figure 1. Phenotypic Characteristics of
Each Individual with CLIFAHDD Syndrome
Four individuals affected by CLIFAHDD
syndrome; all individuals shown have
NALCN mutations. Note the short palpe-
bral fissures, flattened nasal root and
bridge, large nares, long philtrum, pursed
lips, H-shaped dimpling of the chin, and
deep nasolabial folds (A, B, C1, D). Camp-
todactyly of the digits of the hands and
ulnar deviation of the wrist (A, B, C, D1,
D2) or clubfoot (C3) is present in each
affected person. Case identifiers for the
individuals shown in this figure corre-
spond to those in Table 1, where there is
a detailed description of the phenotype
of each affected individual. Figure S1
provides a pedigree of each CLIFAHDD-
syndrome-affected family.delay (Table 1, family K).We then co-expressedmutant and
wild-type NALCN in HEK293T cells. Immunoblot analysis
demonstrated that the expression of either the p.Tyr578Ser
or p.Leu509Ser (GFP-tagged) NALCN alteration nearly elim-
inated wild-type (HA-tagged) NALCN protein (Figure 3).
It remains to be determined whether synthesis of altered
NALCN channels prevents wild-type NALCN synthesis
or induces its degradation by the proteasome. The latter
mechanism has been previously described14 with regard
to mutations in the Cav1.2 calcium channel responsible
for dominantly inherited episodic ataxia type 2 (MIM
108500). However, preliminary evidence suggests that
NALCN alterations are correctly targeted to the plasma
membrane (data not shown). Nevertheless, both muta-
tions apparently induced the disappearance of wild-type
NALCN to the same extent. Accordingly, an explanation
for the observed phenotypic differences between the
sampled cases is not yet apparent.
Collectively, these functional studies, although prelim-
inary, are consistent with mutations in NALCN causing
CLIFAHDD syndrome via a dominant-negative effect
that results in haploinsufficiency. However, the finding
that persons heterozygous for NALCN mutations that
cause IHPRF are reportedly unaffected indicates that
haploinsufficiency of NALCN alone is not adequate to
cause CLIFAHDD syndrome. These observations suggest
that NALCN mutations that cause CLIFAHDD syndrome
might produce a mutant protein that has some residual
activity (i.e., a hypomorphic allele) or that exhibits a
gain of function. Moreover, mutations in NALCN could
cause CLIFAHDD syndrome by more than one
mechanism.468 The American Journal of Human Genetics 96, 462–473, March 5, 2015NALCN is a G-protein-coupled re-
ceptor-activated channel15 consisting
of four homologous domains (do-
mains I–IV), each of which consists
of six transmembrane segments (S1–
S6) separated by cytoplasmic linkers
(Figure 2). Pore-forming loops (Ploops) between S5 and S6 of each domain form an EEKE so-
dium-ion selectivity filter (Figure 2). In vertebrates and
some invertebrate model organisms, such as Drosophila
and C. elegans, NALCN has a sodium-selective EEKE pore
and putatively functions as a sodium channel. However,
it remains unclear whether NALCN is actually an ion chan-
nel rather than a sensor of sodium.16 In mammals, NALCN
is most highly expressed in the central nervous system but
is also found at moderate levels in the heart, lymph nodes,
pancreas, and thyroid (summarized by Cochet-Bissuel
et al.17). Unlike most known genes underlying DA syn-
dromes, NALCN is not expressed in fetal skeletal muscle
(Figure S4). However, homologs of NALCN are expressed
in the neuromuscular junction in D. melanogaster18 as
well as in motor neurons in C. elegans19 and mice.20,21
Accordingly, mutations in NALCN might cause congenital
contractures by disturbingmotor control of myofiber func-
tion during development, similar to the hypothesized ef-
fects of mutations in ECEL1, PIEZO2, and CHRNG (MIM
100730).
Each of the 14 de novo NALCN mutations found to
cause CLIFAHDD syndrome is located in or near the
predicted S5 and S6 segments, which are part of the pore-
forming domain of the NALCN channel (Figure 2;
Table S1). The clustering of mutations is an indication
of the functional importance of these segments. In
contrast, the frameshift (c.1489delT [p.Tyr497Thrfs21])
and nonsense (c.1924C>T [p.Gln642Ter]) mutations re-
ported to cause IHPRF are predicted to result in a loss of
function of NALCN, whereas the missense (c.3860G>T
[p.Trp1287Leu]) mutation is predicted to alter the S3
segment of domain IV. These findings suggest that
AB
C
Figure 2. Genomic and Protein Structure of NALCN and Spectrum of Mutations that Cause CLIFAHDD Syndrome
(A) NALCN is composed of 45 exons, 43 of which are protein coding (blue) and two of which are non-coding (orange). Lines with
attached dots indicate the approximate locations of 14 different de novo variants that cause CLIFAHDD syndrome. The color of each
dot reflects the nearest transmembrane segment (S1–S6) depicted in (B) and (C). The two mutations between IIIS6 and IVS1 are located
in the intracellular loop linking domains III and IV. This loop is known to be involved in the inactivation of voltage-gated sodium chan-
nels; however NALCN is not voltage-gated, so the specific function of this loop in NALCN is not known.
(B) The predicted protein topology of NALCN is comprised of four homologous pore-forming domains (I–IV), each composed of six
transmembrane segments (S1–S6). The bold line represents the polypeptide chain linking segments and domains. The outer ring of P
loop amino acid residues (EEKE) that form the ion selectivity filter is represented by filled circles. The approximate positions of variants
that cause CLIFAHDD syndrome and infantile hypotonia with psychomotor retardation and characteristic facies are indicated by red-
filled circles and black-filled circles, respectively.
(C) S1–S3 might have structural functions, whereas four P loops spanning from S5 to S6 form the ion selectivity filter. In other 4x6TM
protein superfamily channels, such as SCN1A, the S4 segments initiate opening of the central pore (S5-P loop-S6) in response to voltage
changes, however, because NALCN is not voltage-gated, the function of S4 is currently unknown.mutations in different regions of NALCN perturb different
functions of the channel, result in different Mendelian
conditions, and determine whether the condition is
transmitted in an autosomal-recessive or an autosomal-
dominant pattern. A similar relationship has recently
been reported for MAB21L2 (MIM 604357) mutations
that underlie a spectrum of major malformations of the
eye.22
NALCN is highly conserved across vertebrates, and there
is ~98% sequence identity between human and mouse
NALCN. Functional studies in model organisms have illu-
minated multiple physiologic roles of NALCN. In general,
NALCN permits background sodium-ion leak currents that
contribute to regulation of resting membrane potentials
and spontaneous firing of motor neurons.23 In mice,
NALCN has been shown to regulate respiration,24 intesti-
nal pacemaking activity in the interstitial cells of Cajal,25
and serum sodium concentration.26 Mutation of NALCN
homologs in D. melanogaster, C. elegans, and L. stagnalis
results in abnormal locomotion,19,27–30 disturbance of
circadian rhythms,29 disruption of normal respiratory
rhythms,31 and altered sensitivity to ethanol and some
general anesthetics30,32,33 (reviewed by Cochet-Bissuel
et al.17). Homozygous Nalcn-null mice die shortly after
birth and exhibit disrupted respiratory rhythm; mutant
pups breath for 5 s, followed by 5 s of apnea. This disruptedThe Amerespiratory rhythm results from a lack of electrical dis-
charges from the C4 nerves that control the thoracic
diaphragm.24 Interstitial cells of Cajal, which generate
the electrical signals that govern gut motility, from
Nalcn-null mice exhibit abnormal regulation of pace-
making activity.25 These abnormalities are reminiscent
of some of the respiratory and gastrointestinal abnormal-
ities observed in persons with CLIFAHDD syndrome.
Moreover, gain-of-function mutations in exons encoding
segment S6 of domain I of a NALCN homolog (nca-1) in
C. elegans lead to a dominantly inherited phenotype that
includes pausing and uncoordinated, exaggerated body
bending19,34 and loosely recapitulates episodes of disorga-
nized movement experienced by several individuals with
CLIFAHDD syndrome. Nevertheless, these assertions are
based on anecdotal clinical information and necessitate
objective testing of respiratory function and gastrointes-
tinal motility.
NALCN is part of a structurally similar superfamily
(the 4x6TM family) of cation (i.e., sodium and calcium)
channels with four homologous domains containing six
transmembrane helices.16 Mutations in 4x6TM genes that
encode voltage-gated sodium and calcium channels (e.g.,
SCN1A [MIM 182389], SCN9A [MIM 603415], CACNA1A
[MIM 601011], and CACNA1C [MIM 114205]) can cause
developmental delay, intellectual disability, seizures,rican Journal of Human Genetics 96, 462–473, March 5, 2015 469
Figure 3. Expression of p.Tyr578Ser and p.Leu509Ser NALCN
Alterations Prevents Wild-Type NALCN Detection at the Protein
Level when Co-Expressed in HEK293T Cells
HA-taggedwild-type NALCN channels are not detectable when co-
expressed with GFP-tagged NALCN mutant channels in HEK293T
cells but are detectable when co-expressed with GFP-tagged wild-
type NALCN channels. This experiment is representative of four
independent experiments.myotonia, ataxia, pain hypersensitivity and insensitivity,
and cardiac arrhythmias. These conditions are far more
common than CLIFAHDD syndrome (hundreds of different
mutations have been reported to date), and for some con-
ditions, significant structure-function relationships have
been described.35,36 Caution is warranted, however, in
trying to use these observations to make inferences about
structure-function relationships in NALCN because NALCN
is not a paralog of these genes but instead diverged from
them prior to the diversification of 4x6TM voltage-gated
calcium and sodium channels in animals.37,38
In 2003, we reported that mutations in TNNI2 and TPM2
caused DA1 and hypothesized that DA syndromes are, in
general, caused by mutations in genes that encode compo-
nents of the contractile apparatus of fast-twitch skeletal
myofibers.1 Over the past decade, we and others have
identified, via a candidate-gene approach, mutations
that cause DA conditions in four additional genes (i.e.,
TNNT3,2 MYH3,3 MYH8,39and MYBPC140 [MIM 160794])
that encode contractile proteins. However, mutations in
these six genes collectively explain only ~60% of affected
families. In the past 2 years, exome sequencing has
facilitated discovery of mutations in two genes, PIEZO2
(MIM 613629), which causes DA3 (Gordon syndrome470 The American Journal of Human Genetics 96, 462–473, March 5[MIM 114300])41 and DA5 (MIM 108145),41,42 and ECEL1
(MIM 605896), which causes DA5D (MIM 615065).43,44 In
contrast to genes that encode contractile proteins, PIEZO2
is a mechanoreceptor, and ECEL1 plays a role in the devel-
opment of terminal neuronal branches at skeletal-muscle
endplates. These discoveries confirmed that a subset of
DA syndromes are due to a mechanism(s) other than
perturbation of the contractile apparatus of skeletal myo-
fibers. The finding that mutations in NALCN underlie
some individuals’ diagnoses of atypical DA, most often
DA2Awith neurological impairment, suggests that NALCN
should be added to the expanding list of genes that are
causal for DA conditions but do not encode contractile
proteins. However, in each person with a NALCN muta-
tion, the diagnosis of DA should have been excluded
because neurological abnormalities, including hypotonia
and developmental delay, are explicit exclusion criteria.45
In other words, CLIFAHDD syndrome is a newly delineated
Mendelian condition and one of more than 300 condi-
tions characterized by arthrogryposis, but it is not a DA
syndrome.
Descriptions of several children with clinical characteris-
tics similar to those of CLIFAHDD syndrome have been
reported previously. Specifically, in the early 1990’s four in-
dependent simplex families were described46,47 as exhibit-
ing ‘‘distal arthrogryposis, mental retardation, whistling
face, and Pierre Robin sequence,’’ currently designated as
Illum syndrome (MIM 208155). Three of these children,
including two who died at six months of age, died prema-
turely. In each instance, the facial characteristics, neuro-
logical findings, and natural history parallel those found
in CLIFAHDD syndrome. Accordingly, we suspect that
these children likely had mutations in NALCN. However,
we note that Illum et al.48 reported a family with three
affected siblings whose phenotypic features overlapped
with but were distinctly different from those found in
CLIFAHDD syndrome. Most notably, the affectedmembers
of the family reported by Illum et al. had calcium deposi-
tion in the skeletal muscle and central nervous system,
whereas this is not typical of individuals with CLIFAHDD
syndrome. Thus, we conclude that Illum and CLIFAHDD
syndromes are different conditions.
In summary, we used exome and targeted next-genera-
tion sequencing to identify de novo mutations in NALCN
as the cause of a newly delineated condition, CLIFAHDD
syndrome, characterized by congenital contractures of
the limbs and face, hypotonia, and developmental delay.
The range of phenotypic variation in the CLIFAHDD-syn-
drome-affected individuals described herein is relatively
narrow, but the congenital contractures were mild enough
in some cases to have been overlooked, particularly in
older children and young adults. Accordingly, it is possible
that mutations inNALCNmight also explain some cases of
apparently isolated intellectual disability. Furthermore, the
finding that the de novo mutations cluster in and around
the pore-forming regions (i.e., S5 and S6 helices) suggests
that the location and type of NALCN mutations might, 2015
determine whether an individual develops IHPRF or
CLIFAHDD syndrome.Supplemental Data
Supplemental Data include four figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2015.01.003.Consortia
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